https://www.thebodypro.com/category/fda-approved-hiv-medications/tag/lipodystrophy-body-fat
FDA-Approved HIV Medications

Lipodystrophy/Body Fat

The Latest

Promo Image

Protein Accumulation Might Cause Fat Deposits, Other Side Effects in HIV-Positive People Taking Protease Inhibitors, Study Says

Similarities between genetic conditions that cause early aging and side effects experienced by some HIV-positive people when taking protease inhibitors might explain the fat accumulation associated with the drugs, according to a study published Monda...

By Henry J. Kaiser Family Foundation
Promo Image

Protease Inhibitors Not Associated With Fat Gain; Some Antiretrovirals Can Cause Fat Loss, Study Says

Although some antiretroviral drugs are associated with weight loss in the extremities in HIV-positive men, weight gain is not associated with taking protease inhibitors, according to a study published in the Oct. 1 issue of the Journal of Acquired Im...

By Henry J. Kaiser Family Foundation
Promo Image

Evaluation of Coronary Artery Calcification by Electron Beam Computed Tomography in HIV-Infected Men Receiving Prolonged Protease Inhibitor Therapy

Evaluation of Coronary Artery Calcification by Electron Beam Computed Tomography (EBCT) in HIV-Infected Men Receiving Prolonged Protease Inhibitor (PI) Therapy (Oral 25) Authored by David M. Parenti, Madeline M. Rice, Afsoon Roberts, Angelike L...

By Judith A. Aberg, M.D., F.I.D.S.A.
Promo Image

Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study

Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study (Abstract 28) Presented by David Nolan

Two important studies were presented back to back. David No...

By Pablo Tebas, M.D.
Promo Image

Select HIV Protease Inhibitors Alter Bone and Fat Metabolism In Vitro

Select HIV Protease Inhibitors Alter Bone and Fat Metabolism In Vitro Abstract 219 Authored by Renu G. Jain, A. Payne, J.M. Lenhard (GlaxoSmithKline Inc, RTP, NC) View the original abstract

The first reports of what we would come to ca...

By Alvan E. Fisher, M.D.
Promo Image

The Impact of First Line Therapies on Lipid Metabolism: The FRAMS Data

The Impact of First Line Therapies on Lipid Metabolism: The FRAMS Data Presented by P. Reiss Switching From PI-Based to NNRTI-Based Regimens: Clinical and Metabolic Outcomes Presented by B. Clotet

Metabolic problems remain a major concer...

By Brian A. Boyle, M.D., J.D.